Back to Search Start Over

In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013.

Authors :
Hui Liu
Heng-lin Yang
Lin-hua Tang
Xing-liang Li
Fang Huang
Jia-zhi Wang
Chun-fu Li
Heng-ye Wang
Ren-hua Nie
Xiang-rui Guo
Ying-xue Lin
Mei Li
Jian Wang
Jian-wei Xu
Source :
Malaria Journal; 2015, Vol. 14 Issue 1, p1-8, 8p, 3 Charts, 1 Graph, 1 Map
Publication Year :
2015

Abstract

Background: Artemisinin-based combination therapy (ACT) is the recommended first-line treatment of falciparum malaria in all endemic countries. Artemisinin resistance in Plasmodium falciparum has been confirmed in the Greater Mekong subregion (GMS). Dihydroartemisinin-piperaquine (DAPQ) is the most commonly used ACT in China. To understand the DAPQ sensitivity of P. falciparum, DAPQ resistance was monitored in vivo along the China-Myanmar border from 2007 to 2013. Methods: Eligible patients with mono-infections of P. falciparum were recruited to this study after obtaining full informed consent. DAPQ tablets for different categories of kg body weight ranges were given once a day for three days. Patients were followed up for 42 days. Polymerase chain reaction (PCR) was conducted to distinguish between re-infection and recrudescence, to confirm the Plasmodium species. The data were entered and analysed by the Kaplan-Meier method. Treatment outcome was assessed according to the WHO recommended standards. Results: 243 patients were completed valid follow-up. The fever clearance time (FCT) and asexual parasite clearance times (APCT) were, respectively, 36.5 ± 10.9 and 43.5 ± 11.8 hours, and there was an increasing trend of both FCT (F = 268.41, P < 0.0001) and APCT (F = 88.6, P < 0.0001) from 2007 to 2013. Eight (3.3%, 95% confidence interval, 1.4-6.4%) patients present parasitaemia on day three after medication; however they were spontaneous cure on day four. 241 (99.2%; 95% CI, 97.1-99.9%) of the patients were adequate clinical and parasitological response (ACPR) and the proportions of ACPR had not changed significantly from 2007 to 2013 (X² = 2.81, P = 0.7288). Conclusion: In terms of efficacy, DAPQ is still an effective treatment for falciparum malaria. DAPQ sensitivity in P. falciparum had not significantly changed along the China-Myanmar border of Yunnan Province, China. However more attentions should be given to becoming slower fever and parasite clearance. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14752875
Volume :
14
Issue :
1
Database :
Complementary Index
Journal :
Malaria Journal
Publication Type :
Academic Journal
Accession number :
101992915
Full Text :
https://doi.org/10.1186/s12936-015-0584-8